Filing Details

Accession Number:
0001209191-23-051191
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-02 18:19:48
Reporting Period:
2023-09-28
Accepted Time:
2023-10-02 18:19:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1601830 Recursion Pharmaceuticals Inc. RXRX Biological Products, (No Disgnostic Substances) (2836) 464099738
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1856414 Marriott Tina Larson 41 S. Rio Grande Street
Salt Lake City UT 84101
President And Coo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2023-09-28 3,000 $1.06 421,782 No 4 M Direct
Class A Common Stock Disposition 2023-09-28 3,000 $7.72 418,782 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Stock Option (Right to Buy) Disposition 2023-09-28 3,000 $0.00 3,000 $1.06
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
526,000 2028-07-22 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Class A Common Stock Stock Option (Right to Buy) $8.55 2033-02-01 0 434,122 Direct
Class A Common Stock Stock Option (Right to Buy) $11.40 2032-02-04 0 159,226 Direct
Class A Common Stock Stock Option (Right to Buy) $11.40 2022-02-04 2032-02-04 0 4,784 Direct
Class A Common Stock Stock Option (Right to Buy) $2.48 2030-12-30 0 150,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2033-02-01 0 434,122 Direct
2032-02-04 0 159,226 Direct
2032-02-04 0 4,784 Direct
2030-12-30 0 150,000 Direct
Footnotes
  1. Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023.
  2. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.56 to $7.83 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
  3. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
  4. Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
  5. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
  6. One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.